IFR:上海微創醫療機器人計劃進行規模至多10億美元的香港IPO
IFR援引未具名知情人士報道,上海微創醫療機器人計劃今年通過香港IPO融資約7億至10億美元。中金和摩根大通牽頭IPO事宜。
上海微創醫療機器人(集團)股份有限公司,是微創醫療科學有限公司(00853.HK)旗下子集團,於2014年組建團隊並開始研發工作, 致力於面向微無創手術最前沿發展需求,運用機器人、智能控制、傳感與信息領域的前沿研究和產業集成,創新性提供能夠延長和重塑生命的機器人智能手術全解方案。引領機器人手術的成熟與發展,塑造機器人智能手術時代。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.